Compugen (CGEN) Capital Expenditures (2009 - 2010)
Compugen (CGEN) reported Capital Expenditures of $88000.0 for Q4 2010, up 23.94% on a YoY basis from $71000.0 in Q4 2009, and up 344.44% sequentially from -$36000.0 in Q3 2010.
Compugen (CGEN) Capital Expenditures (2009 - 2010) Analysis & Trends
Compugen (CGEN) has 2 years of Capital Expenditures data on file, last reported at $88000.0 in Q4 2010.
- For the quarter ending Q4 2010, Capital Expenditures rose 23.94% year-over-year to $88000.0; the trailing twelve-month figure through Dec 2010 stood at $112000.0 (changed N/A YoY), and the FY2025 full-year result was $306000.0, up 159.32% from the prior year.
- Capital Expenditures improved to $88000.0 in Q4 2010, from -$36000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $88000.0 in Q4 2010 to a low of -$36000.0 in Q3 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Compugen | 221.26 Mn | 129.51 Mn | 352,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2010 | 88,000.00 |
| Dec 31, 2010 | 88,000.00 |
| Sep 30, 2010 | -36,000.00 |
| Sep 30, 2010 | -36,000.00 |
| Dec 31, 2009 | 71,000.00 |
| Dec 31, 2009 | 71,000.00 |
| Sep 30, 2009 | -11,000.00 |
| Sep 30, 2009 | -11,000.00 |